Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 6:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 102 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Alzheimer Disease 1 Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Study Of Single Ascending And Multiple Doses Of PF-04447943 In Japanese Subjects.

NCT00959803
View directory record Official record
Conditions
Healthy
Interventions
PF-04447943, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 85 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 6, 2009 · Synced Jul 23, 2026, 6:23 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

A First-in-Human Study to Assess Single Doses of APNmAb005 in Healthy Participants

NCT05344989
View directory record Official record
Conditions
Healthy Volunteers, Tauopathies, Alzheimer Disease
Interventions
APNmAb005, Placebo
Drug
Lead sponsor
APRINOIA Therapeutics, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Jul 23, 2026, 6:23 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study in Subjects With Mild-to-Moderate Alzheimer's Dementia

NCT05834296
View directory record Official record
Conditions
Alzheimer Disease
Interventions
ALZN002 (autologous DCs pulsed with E22W mutant peptide)., Placebo
Biological · Drug
Lead sponsor
Alzamend Neuro, Inc.
Industry
Eligibility
60 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Doral, Florida
Source: ClinicalTrials.gov public record
Updated Sep 1, 2025 · Synced Jul 23, 2026, 6:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Pharmacokinetics of CMS121, a Drug Candidate for Alzheimer's Disease, in Healthy Subjects

NCT05318040
View directory record Official record
Conditions
Alzheimer Disease
Interventions
CMS121, Placebo
Drug
Lead sponsor
Virogenics, Inc.
Industry
Eligibility
19 Years to 85 Years
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Jul 23, 2026, 6:23 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability, and Blood Levels of ACU193 in Participants With MCI or Mild AD

NCT04931459
View directory record Official record
Conditions
Alzheimer Disease
Interventions
ACU193, Placebo
Drug
Lead sponsor
Acumen Pharmaceuticals
Industry
Eligibility
55 Years to 90 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
17
States / cities
Scottsdale, Arizona • Anaheim, California • Newport Beach, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Jul 23, 2026, 6:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, Two-part, Randomized Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Liquid Formulation of Tricaprilin and Matching Placebo in Healthy Subjects

NCT05408780
View directory record Official record
Conditions
Alzheimer Disease
Interventions
AC-OLE-01-VA
Drug
Lead sponsor
Cerecin
Industry
Eligibility
18 Years to 55 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced Jul 23, 2026, 6:23 AM EDT
Withdrawn No phase listed Observational

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Alzheimer's Disease

NCT04100889
View directory record Official record
Conditions
Alzheimer Disease, Alzheimer Disease 1, Alzheimer Disease 2, Alzheimer Disease 3, Alzheimer Disease 4, Alzheimer Disease 5, Alzheimer Disease 6, Alzheimer Disease 7, Alzheimer Disease 8, Alzheimer Disease 9, Late-Onset, Alzheimer Disease 10, Alzheimer Disease 11, Alzheimer Disease 12, Alzheimer Disease 13, Alzheimer Disease 14, Alzheimer Disease 15, Alzheimer Disease 16, Alzheimer Disease 17, Alzheimer Disease 18, Alzheimer Disease 19, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Alzheimer Disease Focal
Interventions
No Intervention
Other
Lead sponsor
ProgenaBiome
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Jul 23, 2026, 6:23 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Physical Activity and Community EmPOWERment Project

NCT06740162
View directory record Official record
Conditions
Intellectual Disability, Neurodevelopmental Disorders, Autism Spectrum Disorder, Down Syndrome, Fragile X Syndrome, Cri-du-Chat Syndrome, De Lange Syndrome, Mental Retardation, X-Linked, Prader-Willi Syndrome, Rubinstein-Taybi Syndrome, Trisomy 13 Syndrome, WAGR Syndrome, Williams Syndrome
Interventions
PACE Program
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
376 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
2
States / cities
Fayetteville, Arkansas • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Jul 23, 2026, 6:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Pharmacokinetics and Pharmacodynamics of Velusetrag in Healthy Elderly Subjects

NCT01467726
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Velusetrag, Placebo
Drug
Lead sponsor
Alfasigma S.p.A.
Industry
Eligibility
65 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Jul 7, 2025 · Synced Jul 23, 2026, 6:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study of VG-3927 in Healthy Adults and Patients With Alzheimer's Disease

NCT06343636
View directory record Official record
Conditions
Healthy, Alzheimer Disease
Interventions
VG-3927, Placebo
Drug
Lead sponsor
Vigil Neuroscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
2
States / cities
Maitland, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Jul 23, 2026, 6:23 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of Ad4-HIV Envelope Vaccine Vectors in Healthy Volunteers

NCT03878121
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Ad4-Env145NFL, Ad4-Env150KN, VRC-HIVRGP096-00-VP (Trimer 4571) with alum
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Jul 23, 2026, 6:23 AM EDT
Completed Phase 1 Interventional Results available

A Brief Study To Evaluate The Safety, Tolerability, And Blood Levels Of Multiple Doses Of PF-044467943 Or Placebo In Combination With Donepezil In Subjects With Mild To Moderate Alzheimer's Disease

NCT00988598
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
PF-04447943, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
55 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Glendale, California • Gainesville, Florida • Hallandale, Florida
Source: ClinicalTrials.gov public record
Updated Nov 18, 2020 · Synced Jul 23, 2026, 6:23 AM EDT
Completed Phase 1 Interventional

A Phase 1 Study of the Safety, Tolerability and Pharmacokinetics of ABT-126 in Subjects With Alzheimer's Disease

NCT01482845
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
ABT-126, Placebo
Drug
Lead sponsor
Abbott
Industry
Eligibility
55 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
3
States / cities
Glendale, California • Hallandale, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated May 1, 2012 · Synced Jul 23, 2026, 6:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Two-part Multiple Dose Study to Assess the Safety and Effects of AZD3293 in Healthy Elderly and Alzheimer's Patients

NCT01795339
View directory record Official record
Conditions
Healthy Elderly Volunteers, Mild-to-moderate Alzheimer's Disease Patients
Interventions
AZD3293, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
55 Years to 80 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Apr 2, 2014 · Synced Jul 23, 2026, 6:23 AM EDT
Completed Phase 1Phase 2 Interventional

Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis

NCT03236792
View directory record Official record
Conditions
AL Amyloidosis
Interventions
Ixazomib, Cyclophosphamide, Dexamethasone
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Jul 23, 2026, 6:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Comparing the Safety, Tolerability, and Pharmacokinetics of Sabirnetug IV and Sabirnetug + rHuPH20 SC in Healthy Participants

NCT06511570
View directory record Official record
Conditions
Alzheimer Disease
Interventions
sabirnetug (ACU193), Sabirnetug + rHuPH20
Drug · Combination Product
Lead sponsor
Acumen Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Jul 23, 2026, 6:23 AM EDT
Completed Phase 3 Interventional Results available

A Study of Semagacestat for Alzheimer's Patients

NCT01035138
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
semagacestat
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
41
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2014 · Synced Jul 23, 2026, 6:23 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Game-based Pediatric Diabetes Education

NCT06264258
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Behavior, Health
Interventions
DVx-T1D™ app
Behavioral
Lead sponsor
Carnegie Mellon University
Other
Eligibility
6 Years to 12 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Jul 23, 2026, 6:23 AM EDT
Completed Phase 2 Interventional

Impact of Grape Consumption on Brain Metabolism and Neuropsychological Performance Over 1 Year

NCT03361410
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Grape Powder, Placebo Powder
Dietary Supplement
Lead sponsor
University of California, Los Angeles
Other
Eligibility
65 Years to 85 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 20, 2023 · Synced Jul 23, 2026, 6:23 AM EDT
Recruiting Phase 2 Interventional

A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)

NCT07589595
View directory record Official record
Conditions
Cognitive Dysfunction, Lewy Body Disease, Synucleinopathies, Amyloid
Interventions
Donanemab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years to 85 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
42
States / cities
Chandler, Arizona • Scottsdale, Arizona • Carlsbad, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 23, 2026, 6:23 AM EDT
Completed Phase 1Phase 2 Interventional

Gene Therapy for APOE4 Homozygote of Alzheimer's Disease

NCT03634007
View directory record Official record
Conditions
Alzheimer Disease, Early Onset Alzheimer Disease
Interventions
LX1001
Biological
Lead sponsor
Lexeo Therapeutics
Industry
Eligibility
50 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
4
States / cities
Maitland, Florida • Orlando, Florida • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Jul 23, 2026, 6:23 AM EDT
Completed Phase 2 Interventional

Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD)

NCT00104273
View directory record Official record
Conditions
Dementia, Alzheimer's Disease
Interventions
Rasagiline
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
45 Years to 90 Years
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
31
States / cities
Huntsville, Alabama • Tucson, Arizona • Little Rock, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2009 · Synced Jul 23, 2026, 6:23 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Dominantly Inherited Alzheimer Network (DIAN)

NCT00869817
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2026
U.S. locations
8
States / cities
Jacksonville, Florida • Indianapolis, Indiana • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Jul 23, 2026, 6:23 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (XanADu)

NCT02727699
View directory record Official record
Conditions
Dementia, Alzheimer Type
Interventions
Xanamem™, Placebo (for Xanamem™)
Drug
Lead sponsor
Actinogen Medical
Industry
Eligibility
50 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
14
States / cities
Tucson, Arizona • Los Angeles, California • Poway, California + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Jul 23, 2026, 6:23 AM EDT